NO982599L - Antifungale sammensetninger med forbedret biotilgjenelighet - Google Patents

Antifungale sammensetninger med forbedret biotilgjenelighet

Info

Publication number
NO982599L
NO982599L NO982599A NO982599A NO982599L NO 982599 L NO982599 L NO 982599L NO 982599 A NO982599 A NO 982599A NO 982599 A NO982599 A NO 982599A NO 982599 L NO982599 L NO 982599L
Authority
NO
Norway
Prior art keywords
improved bioavailability
antifungal compositions
antifungal
compositions
bioavailability
Prior art date
Application number
NO982599A
Other languages
English (en)
Other versions
NO320495B1 (no
NO982599D0 (no
Inventor
Lieven Elvire Colette Baert
Geert Verreck
Dany Thonu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26142825&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO982599(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO982599D0 publication Critical patent/NO982599D0/no
Publication of NO982599L publication Critical patent/NO982599L/no
Publication of NO320495B1 publication Critical patent/NO320495B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
NO19982599A 1996-05-20 1998-06-05 Intrakonazolininneholdende partikler og farmasoytiske doseringsformer inneholdende disse samt fremgamsmater for fremstilling av det samme NO320495B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201430 1996-05-20
EP97200698 1997-03-07
PCT/EP1997/002507 WO1997044014A1 (en) 1996-05-20 1997-05-12 Antifungal compositions with improved bioavailability

Publications (3)

Publication Number Publication Date
NO982599D0 NO982599D0 (no) 1998-06-05
NO982599L true NO982599L (no) 1998-11-19
NO320495B1 NO320495B1 (no) 2005-12-12

Family

ID=26142825

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982599A NO320495B1 (no) 1996-05-20 1998-06-05 Intrakonazolininneholdende partikler og farmasoytiske doseringsformer inneholdende disse samt fremgamsmater for fremstilling av det samme

Country Status (34)

Country Link
US (4) US6509038B2 (no)
EP (1) EP0904060B1 (no)
JP (1) JP3391801B2 (no)
KR (1) KR19990044257A (no)
CN (1) CN1165291C (no)
AR (1) AR007195A1 (no)
AT (1) ATE255883T1 (no)
AU (1) AU722101B2 (no)
BG (1) BG64368B1 (no)
BR (1) BR9706897B1 (no)
CA (1) CA2240161C (no)
CY (1) CY2434B1 (no)
CZ (1) CZ293841B6 (no)
DE (1) DE69726729T2 (no)
DK (1) DK0904060T3 (no)
EA (1) EA001219B1 (no)
EE (1) EE03902B1 (no)
ES (1) ES2212810T3 (no)
HK (1) HK1018002A1 (no)
HR (1) HRP970270B1 (no)
HU (1) HU227745B1 (no)
ID (1) ID16926A (no)
IL (1) IL124935A (no)
MX (1) MX9805418A (no)
MY (1) MY123827A (no)
NO (1) NO320495B1 (no)
NZ (1) NZ330739A (no)
PL (1) PL188566B1 (no)
PT (1) PT904060E (no)
SI (1) SI0904060T1 (no)
SK (1) SK284145B6 (no)
TR (1) TR199801225T2 (no)
TW (1) TW460282B (no)
WO (1) WO1997044014A1 (no)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
PT1039909E (pt) 1997-12-31 2003-02-28 Choongwae Pharma Corp Metodo de producao e composicao de uma preparacao oral de itraconazole
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
KR100288890B1 (ko) * 1997-12-31 2001-05-02 최현식 이트라코나졸 경구용 제제 및 그의 제조방법
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
IL145140A0 (en) * 1999-03-24 2002-06-30 Fmc Corp Improved aqueous solubility pharmaceutical formulations
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
ES2398643T3 (es) * 1999-12-23 2013-03-20 Mayne Pharma International Pty Ltd. Composiciones farmacéuticas mejoradas para fármacos escasamente solubles
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
BR0111868A (pt) * 2000-06-22 2003-07-01 Novartis Ag Composições farmacêuticas
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
ATE343567T1 (de) 2001-02-14 2006-11-15 Tibotec Pharm Ltd Breitspektrum 2-(substituierte-amino)- benzothiazol-sulfonamide hiv protease inhibitoren
EP1397367A2 (en) 2001-04-09 2004-03-17 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
NZ529250A (en) 2001-05-11 2005-05-27 Tibotec Pharm Ltd Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors
AU2002317063A (en) * 2001-06-12 2002-12-23 Smartrix Technologies Inc Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
UA79248C2 (en) 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
TWI336621B (en) 2001-12-21 2011-02-01 Tibotec Pharm Ltd Broad spectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
CN1630629B (zh) * 2002-02-28 2010-05-05 日本烟草产业株式会社 酯化合物及其医药用途
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
CA2485903C (en) 2002-05-17 2011-08-16 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
CN1318019C (zh) * 2002-07-04 2007-05-30 詹森药业有限公司 包含两种不同聚合物骨架的固体分散体
EA010486B1 (ru) 2002-08-14 2008-10-30 Тиботек Фармасьютикалз Лтд. Замещенные оксиндолсульфонамидные ингибиторы вич-протеазы широкого спектра действия
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
ATE357235T1 (de) * 2003-01-14 2007-04-15 Cimex Pharma Ag Bioaequivalente zusammensetzung in der form einer festen dispersion enthaltend itraconazol und ein hydrophiles polymer
JP4783278B2 (ja) * 2003-02-03 2011-09-28 ノバルティス アーゲー 医薬製剤
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
CN1822843B (zh) * 2003-07-17 2010-04-28 泰博特克药品有限公司 制备含有抗病毒药物颗粒的方法
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP4832897B2 (ja) * 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
AU2004269930B2 (en) 2003-09-11 2011-08-04 Tibotec Pharmaceuticals Ltd. Entry inhibitors of the HIV virus
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
AU2005219443A1 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
EP1750696B1 (en) 2004-05-07 2013-06-26 Sequoia Pharmaceuticals Inc RETROVIRAL PROTEASE INHIBITORS RESISTING THEIR RESISTANCE
AU2005243439B2 (en) 2004-05-17 2011-09-29 Tibotec Pharmaceuticals Ltd. 1-heterocyclyl-1,5-dihydro-pyrido(3,2-b)indol-2-ones
RU2377243C2 (ru) 2004-05-17 2009-12-27 Тиботек Фармасьютикалз Лтд. 6,7,8,9-ЗАМЕЩЕННЫЕ 1-ФЕНИЛ-1,5-ДИГИДРОПИРИДО (3,2-b) ИНДОЛ-2-ОНЫ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ АНТИИНФЕКЦИОННЫХ ФАРМАЦЕВТИЧЕСКИХ СРЕДСТВ
AR052304A1 (es) 2004-05-17 2007-03-14 Tibotec Pharm Ltd Compuestos 1,5- dihidro - pirido (3,2-b ) indol-2-onas4- sustituidos, composicion farmaceutica y proceso de preparacion del compuesto
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
KR100708974B1 (ko) * 2004-07-19 2007-04-18 주식회사종근당 수용성 수지를 이용한 이트라코나졸 고체분산체
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
BRPI0516772A (pt) * 2004-10-25 2008-09-23 Japan Tobacco Inc formulação sólida com solubilidade e estabilidade melhoradas e método para produção da referida formulação
CA2598204C (en) * 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
EP1912625B1 (en) 2005-08-08 2016-04-13 AbbVie Deutschland GmbH & Co KG Itraconazole compositions with improved bioavailability
PT1912626T (pt) 2005-08-08 2016-07-20 Abbvie Deutschland Formas farmacêuticas com biodisponibilidade melhorada
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
WO2007095716A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
CN101415708A (zh) 2006-04-03 2009-04-22 泰博特克药品有限公司 抑制HIV的3,4-二氢-咪唑并[4,5-b]吡啶-5-酮
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
EP2526932B1 (en) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
US20100003332A1 (en) * 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
JP6073043B2 (ja) * 2007-08-21 2017-02-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医薬品適用のための熱−動力学的混合
WO2009034558A2 (en) 2007-09-14 2009-03-19 Wockhardt Research Centre Rhein or diacerein compositions
CA2926563A1 (en) 2007-09-27 2009-04-02 Wockhardt Research Centre Pharmaceutical compositions of rhein or diacerein
US20090130160A1 (en) * 2007-11-21 2009-05-21 Fiber Innovation Technology, Inc. Fiber for wound dressing
CA2707161C (en) 2007-11-28 2016-08-16 Sequoia Pharmaceuticals, Inc. Compositions and methods for inhibiting cytochrome p450 2d6
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP2011509283A (ja) * 2008-01-11 2011-03-24 シプラ・リミテッド 固体医薬剤形
CA2716348C (en) 2008-02-21 2017-04-04 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2285351A2 (en) * 2008-04-15 2011-02-23 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EA013132B1 (ru) * 2008-12-31 2010-02-26 Открытое Акционерное Общество "Верофарм" Противогрибковое средство для вагинального применения
CN101780046B (zh) * 2009-01-16 2011-09-21 北京化工大学 一种伊曲康唑复合粉体及其制备方法
US10071059B2 (en) 2009-12-18 2018-09-11 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
SG189403A1 (en) * 2010-10-14 2013-05-31 Abbott Gmbh & Co Kg Curcuminoid solid dispersion formulation
CN102068416A (zh) * 2010-12-30 2011-05-25 安徽先求药业有限公司 一种含有伊曲康唑的口服固体制剂及其制备方法
BR112013021030A2 (pt) 2011-02-17 2016-10-11 Hoffmann La Roche processo para cristalização controlada de um ingrediente farmacêutico ativo a partir de estado líquido super-refrigerado por extrusão por fusão a quente
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
CA2844827A1 (en) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
WO2013024358A2 (en) 2011-08-18 2013-02-21 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
EP2760864B1 (en) 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
KR20200065093A (ko) 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
WO2014014752A1 (en) 2012-07-17 2014-01-23 Dow Global Technologies Llc Solid dispersion comprising a highly substituted hydroxyalkyl methylcellulose
BR112015011515A2 (pt) 2012-11-19 2017-08-22 Dr Reddy´S Laboratories Ltd Composições farmacêuticas de inibidores de cetp
WO2014114575A1 (en) 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
US10259921B2 (en) * 2014-01-16 2019-04-16 Dow Global Technologies Llc Support materials for 3D printing
EP3307839B1 (en) * 2015-06-09 2019-02-27 Dow Global Technologies LLC Support materials for 3d printing
US20200009060A1 (en) * 2016-05-09 2020-01-09 Dispersol Technologies, Llc Improved drug formulations
EP3675832A1 (en) 2017-09-01 2020-07-08 Jordan Sweden Medical and Sterilization Company Fast self dispersible dosage forms of deferasirox
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用
US20220304936A1 (en) * 2019-08-28 2022-09-29 Lubrizol Advanced Materials, Inc. Drug-polymer amorphous solid dispersions using linear poly(acrylic acid) polymers
KR102266145B1 (ko) * 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
CN117835971A (zh) 2021-08-25 2024-04-05 巴斯夫欧洲公司 直接压片用辅料组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
ATE5852T1 (de) * 1978-11-20 1984-02-15 American Home Products Corporation Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
JPH0667840B2 (ja) * 1988-11-30 1994-08-31 萬有製薬株式会社 Ｎｂ―８１８の易吸収性製剤
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
WO1993019061A1 (en) * 1992-03-18 1993-09-30 Janssen Pharmaceutica N.V. Itraconazole and saperconazole stereoisomers
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
JP3413238B2 (ja) * 1993-03-31 2003-06-03 オリンパス光学工業株式会社 位相制御膜構造体
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
JP2948111B2 (ja) 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物

Also Published As

Publication number Publication date
CZ188598A3 (cs) 1998-11-11
BR9706897B1 (pt) 2010-09-21
PL188566B1 (pl) 2005-02-28
PT904060E (pt) 2004-04-30
JPH11509238A (ja) 1999-08-17
JP3391801B2 (ja) 2003-03-31
BG64368B1 (bg) 2004-12-30
NO320495B1 (no) 2005-12-12
HRP970270B1 (en) 2005-02-28
EE03902B1 (et) 2002-12-16
MX9805418A (es) 1998-10-31
WO1997044014A1 (en) 1997-11-27
ID16926A (id) 1997-11-20
CY2434B1 (en) 2004-11-12
EA001219B1 (ru) 2000-12-25
BG102532A (en) 1999-02-26
US20140134244A1 (en) 2014-05-15
US20030082239A1 (en) 2003-05-01
US20010007678A1 (en) 2001-07-12
ES2212810T3 (es) 2004-08-01
KR19990044257A (ko) 1999-06-25
EA199800571A1 (ru) 1998-12-24
HUP9901620A3 (en) 2000-03-28
CZ293841B6 (cs) 2004-08-18
US8591948B2 (en) 2013-11-26
AR007195A1 (es) 1999-10-13
IL124935A0 (en) 1999-01-26
US7081255B2 (en) 2006-07-25
TW460282B (en) 2001-10-21
HUP9901620A2 (hu) 1999-10-28
MY123827A (en) 2006-06-30
HU227745B1 (en) 2012-02-28
CN1165291C (zh) 2004-09-08
SI0904060T1 (en) 2004-04-30
TR199801225T2 (xx) 1998-11-23
CA2240161A1 (en) 1997-11-27
CN1209740A (zh) 1999-03-03
US9642806B2 (en) 2017-05-09
DE69726729D1 (de) 2004-01-22
BR9706897A (pt) 1999-08-31
AU722101B2 (en) 2000-07-20
US20060263436A1 (en) 2006-11-23
IL124935A (en) 2001-06-14
SK284145B6 (sk) 2004-10-05
PL330931A1 (en) 1999-06-07
EP0904060B1 (en) 2003-12-10
NO982599D0 (no) 1998-06-05
ATE255883T1 (de) 2003-12-15
NZ330739A (en) 1999-06-29
US6509038B2 (en) 2003-01-21
HK1018002A1 (en) 1999-12-10
DE69726729T2 (de) 2004-12-02
EP0904060A1 (en) 1999-03-31
AU2956297A (en) 1997-12-09
SK84898A3 (en) 1999-03-12
CA2240161C (en) 2005-05-24
HRP970270A2 (en) 1998-04-30
EE9800304A (et) 1999-02-15
DK0904060T3 (da) 2004-04-13

Similar Documents

Publication Publication Date Title
NO982599L (no) Antifungale sammensetninger med forbedret biotilgjenelighet
DE69707907D1 (de) Herbizid wirkende zusammensetzung
DE69718508D1 (de) Antitraspirant zusammensetzung
ID25508A (id) Komposisi dematologis
DK1021439T3 (da) Krystallinsk antifungal polymorf form
DZ2205A1 (fr) Compositions antifongiques.
ID18359A (id) Komposisi mikrokapsul
ID21009A (id) Komposisi untuk supositori
ID21906A (id) Komposisi adesif
ID19589A (id) Komposisi
DE59712835D1 (de) Stabilisierte monomerenzusammensetzung
DE69710729D1 (de) Fungizide zusammensetzung mit erhörter bioverfügbarkeit
PT867124E (pt) Composicao antifungica
BR9707835A (pt) Composiç
DE69700755D1 (de) Mikrobizide Zusammensetzung
BR9709815A (pt) Composicão
FI19992526A (fi) Sahakokoonpano
DE69700503T2 (de) Fungizide Zusammensetzung
BR9707330A (pt) Composição herbicida
DE69726299D1 (de) Antistatische zusammensetzung
NO991735D0 (no) Vaskemiddelblanding
DE69713462D1 (de) Fungizide Zusammensetzungen
ID17791A (id) Komposisi nonafluorometoksibutana
UA25694A (uk) Фуhгіцидhа композиція
SE9604746D0 (sv) Composition

Legal Events

Date Code Title Description
MK1K Patent expired